Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, 12120, Thailand.
Center of Excellence for Medical Genomics, Medical Genomics Cluster, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Excellence Center for Genomics and Precision Medicine, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, 10330, Thailand.
Eur J Med Genet. 2020 Dec;63(12):104086. doi: 10.1016/j.ejmg.2020.104086. Epub 2020 Oct 9.
Mitochondrial 3-hydroxy-3 methylglutaryl-CoA synthase-2 deficiency (HMGCS2D) is a rare autosomal recessive inborn error of hepatic ketogenesis, caused by mutations in HMGCS2. As its clinical and laboratory manifestations resemble many other metabolic disorders, HMGCS2D definite diagnosis presents a challenge, frequently requiring molecular tests. Only 26 patients with HMGCS2 mutations have been previously described, and this study reports the first two unrelated Thai patients, a 9-month-old male and an 8-month-old female, with HMGCS2D. During acute episodes, steatorrhea and dyslipidemia occurred, both previously unreported. Increased serum levels of triglycerides, very low density lipoproteins (VLDL), and low density lipoproteins (LDL), along with a decreased serum level of HDL were found. Both patients had hypophosphatemic encephalopathy, and the female had metabolic acidosis without hypoglycemia. Trio whole-exome sequencing (WES) revealed that the male harbored two HMGCS2 mutations, a novel c.1480C>T (p.Arg494*) and a previously reported c.1502G>C (p.Arg501Pro), while the female was compound heterozygous for the c.1502G>C (p.Arg501Pro) and a previously reported mutation, c.520T>C (p.Phe174Leu). Interestingly, c.1502G>C (p.Arg501Pro) was not only found in both of our patients but also detected heterozygously in 9 out of 1081 unrelated individuals (allele frequency of 9/2162; 0.42%) in our in-house Thai exome database. Discovery of this common mutation suggests there could be about 14 babies with HMGCS2D within 800,000 newborns in Thailand annually. Therefore, awareness of HMGCS2D among medical personnel in Thailand should be raised.
三羟-3-甲基戊二酰辅酶 A 合酶-2 缺乏症(HMGCS2D)是一种罕见的常染色体隐性遗传性肝酮生成缺陷,由 HMGCS2 基因突变引起。由于其临床表现和实验室表现类似于许多其他代谢紊乱,因此 HMGCS2D 的明确诊断具有挑战性,通常需要进行分子检测。以前仅描述了 26 例 HMGCS2 突变患者,本研究报告了首例两名无关联的泰国患者,一名 9 个月大的男性和一名 8 个月大的女性,患有 HMGCS2D。在急性发作期间,出现了脂肪泻和血脂异常,这两种情况以前都没有报道过。发现血清甘油三酯、极低密度脂蛋白(VLDL)和低密度脂蛋白(LDL)水平升高,而高密度脂蛋白(HDL)水平降低。两名患者均患有低磷性脑病,女性患者伴有代谢性酸中毒而无低血糖。对三人体外显子组测序(WES)显示,男性患者携带两种 HMGCS2 突变,一种新的 c.1480C>T(p.Arg494*)和以前报道过的 c.1502G>C(p.Arg501Pro),而女性患者则是 c.1502G>C(p.Arg501Pro)和以前报道过的突变 c.520T>C(p.Phe174Leu)的复合杂合子。有趣的是,c.1502G>C(p.Arg501Pro)不仅在我们的两名患者中发现,而且在我们的泰国外显子组数据库中的 1081 名无关个体中也有 9 名(杂合子频率为 9/2162;0.42%)发现该突变。这种常见突变的发现表明,泰国每年大约有 14 名患有 HMGCS2D 的新生儿。因此,泰国医务人员应该提高对 HMGCS2D 的认识。